ARA-290

Scientific identity: ARA-290 is an 11-amino-acid cyclic peptide derived from the helix B surface of erythropoietin. The sequence — Cys-His-Gly-Gln-Lys-Leu-Met-Ser-Thr-Thr-Cys — is cyclised through a disulfide bridge between the N-terminal and C-terminal cysteine residues (Cys¹–Cys¹¹), creating a constrained cyclic structure that presents the helix B surface epitope in a conformation selective for IRR engagement over classical EPOR homodimer binding. This selectivity is the defining pharmacological feature studied in ARA-290 research — separating the proposed tissue-protective signalling of EPO from its erythropoietic activity.

Peptide class: Synthetic cyclic undecapeptide; erythropoietin helix B surface peptide; innate repair receptor (IRR) selective agonist; non-erythropoietic EPO-derived peptide.

Primary receptor target: Innate repair receptor (IRR) — a heteroreceptor complex comprising the β common receptor (βcR, CD131) and EPOR — distinct from the classical EPOR homodimer responsible for erythropoiesis. IRR engagement has been studied in tissue protection, anti-inflammatory, and neuroprotective signalling contexts in experimental systems.

Research areas: Innate repair receptor pharmacology, EPO-derived tissue protection biology, small fiber neuropathy research models, neuropathic signalling research, metabolic research in experimental systems, non-erythropoietic EPO signalling, sarcoidosis-associated neuropathy research.

Product quantity: 10mg per vial.

Purity: Greater than 99%, confirmed by HPLC and LC-MS analysis at the batch level.

Analytical documentation: A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability.

Research-use classification: For laboratory research use only. Not for human or veterinary use, clinical diagnostics, or any in-vivo application in humans outside of regulated research settings.

The Innate Repair Receptor and Non-Erythropoietic EPO Signaling

Erythropoietin (EPO) exerts its classical erythropoietic effects through the EPOR homodimer on erythroid progenitor cells, stimulating red blood cell production. A separate EPO receptor complex — the innate repair receptor (IRR), formed by the β common receptor (βcR/CD131) and EPOR as a heterodimer — has been identified in research as a mediator of EPO's proposed tissue-protective signaling in non-erythroid tissues. IRR is expressed in the nervous system, immune cells, pancreatic islets, and other tissues. Research has proposed that IRR engagement mediates protective cellular responses to tissue injury and metabolic stress independently of erythropoiesis.

ARA-290 was designed as a selective IRR agonist — preserving the helix B surface epitope of EPO proposed to engage the IRR while lacking the EPOR homodimer-activating conformation of full-length EPO. This selectivity is studied as a means of investigating IRR-mediated tissue protection biology without the erythropoietic, thrombotic, and cardiovascular effects associated with full-length EPO administration in experimental systems.

Small Fiber Neuropathy and Neuropathic Research

A significant area of ARA-290 research has focused on small fiber neuropathy (SFN) — a neuropathic condition involving dysfunction and loss of small diameter sensory nerve fibers. Research has examined ARA-290 in experimental models of small fiber neuropathy and in human clinical studies, with particular attention to sarcoidosis-associated SFN. Cell-based and animal studies have investigated IRR-mediated signaling in neural cells and dorsal root ganglion models. Human clinical research has examined ARA-290 in sarcoidosis patients with SFN, measuring corneal nerve fiber density and symptom endpoints. These human findings concern pharmaceutical-grade cibinetide under regulated conditions and should not be attributed to the Longevia Research research vial.

Metabolic Research

Research has examined ARA-290 in experimental models involving pancreatic islet biology and insulin secretion, reflecting IRR expression in pancreatic tissue. Animal studies have investigated ARA-290 administration in metabolic models examining glucose homeostasis parameters. These findings are model-specific preclinical observations in defined experimental systems and cannot be extrapolated to human metabolic outcomes.

Research Status

ARA-290 (cibinetide) has been investigated in human clinical trials — most notably in sarcoidosis-associated small fiber neuropathy — but does not hold regulatory approval for any therapeutic indication in any jurisdiction. It remains an active area of clinical and preclinical research. The Longevia Research vial is supplied for Research Use Only with no clinical designation.

Reliable research begins with accurately characterised material. For a cyclic disulfide-containing undecapeptide such as ARA-290, that means confirming sequence integrity, disulfide bridge cyclisation, and purity at the batch level — because the linear reduced form of ARA-290 lacking the Cys¹–Cys¹¹ disulfide bridge presents a different molecular conformation that would not replicate the IRR-selective binding characteristics studied in the published literature, directly confounding receptor pharmacology and signaling experiments.

Purity assessment: Each production lot is characterised to greater than 99% purity by high-performance liquid chromatography (HPLC). Chromatographic purity data is reported on the batch Certificate of Analysis.

Identity confirmation: Peptide identity and disulfide bridge cyclisation are confirmed by mass spectrometry (LC-MS), providing molecular-weight verification consistent with the disulfide-bonded cyclic form. HPLC and LC-MS data together confirm that the material supplied corresponds to the labelled compound at the labelled purity.

Batch traceability and Certificate of Analysis: Every vial of ARA-290 10mg is traceable to a specific production lot. A batch-specific Certificate of Analysis is accessible directly on the Longevia Research website, covering purity, identity, and lot information. Researchers evaluating this material for assay work are encouraged to review the current batch documentation before use, since analytical specifications are applied at the lot level.

Handling: This material should be handled by qualified personnel using appropriate laboratory technique and personal protective equipment, consistent with institutional protocols for research-grade cyclic disulfide-containing synthetic peptides.

Longevia Research supplies ARA-290 10mg for laboratory and in-vitro research use only. The product is intended for use by qualified researchers and trained laboratory personnel in appropriate controlled research environments.

ARA-290 is a synthetic research peptide supplied strictly as a research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. ARA-290 (cibinetide) does not hold regulatory approval for any therapeutic indication in any jurisdiction. Prior human clinical investigation of ARA-290 in sarcoidosis-associated small fiber neuropathy and other indications has not resulted in regulatory approval, and no such approval applies to the Longevia Research research vial, which is not a pharmaceutical product and has not been evaluated by any regulatory authority for safety or efficacy in this formulation.

Longevia provides no dosing instructions, administration guidance, treatment protocols, or reconstitution recommendations for this compound. The scientific literature summarised on this product page describes experimental observations in defined cell-based, animal, and human clinical research systems. Those findings are not medical claims and should not be interpreted as evidence of human efficacy, human safety, or fitness for any clinical application from this product.

The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations. By purchasing this product, the buyer confirms that it will be used solely for legitimate laboratory research purposes by qualified personnel, and that its acquisition and intended use comply with applicable laws in the buyer's jurisdiction.